Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.


  • 45 percent increase in mortality from law enforcement from 1999 to 2013, report shows

  • Magnesium ions show promise in slowing progression of Alzheimer's disease in mice

  • why and when straight women form close friendships with gay men

  • First language wires brain for later language-learning

  • Unfriending on Facebook more likely from politically active users

  • Decline in cognitive ability leads to fear of upfront costs

  • Early progress reported in designing drugs that target 'disordered' proteins

  • Christmas period may reduce quality of life for many Europeans

  • Study 'opens gate' to understanding depression

  • HIV/AIDS drugs interfere with brain's 'Insulation'